JPY 582.00
+4.11%Sep 2, 2026, 22:30 UTC
RaQualia Pharma received a patent allowance in South Korea for a TRPV4 antagonist (pyrimidine-4(3H)-one derivative).
Jul 27, 2026, 11:00 UTC
RaQualia Pharma obtains new indication approval in South Korea for tegoprazan: prevention of peptic ulcers associated with NSAID administration.